To achieve local therapeutic effects on a biological mucosa or to exert systemic therapeutic effects on the circulatory system, mucosal drug delivery systems use a suitable carrier to bring the drug into close contact with the surface of a biological mucosa. Mucosal drug delivery has high bioavailability, quick onset of action, can prolong the drug action time, and can also achieve a certain targeting effect. This is especially true for the gastrointestinal tract, which is not stable or the drugs' hepatic first-pass effect, as peptides and macromolecules can be absorbed through the mucous membrane, expanding the route of drug delivery.
Hydrogels are widely used in mucosal drug delivery systems due to their excellent swelling and mucoadhesive properties. These materials can retain a large amount of water, providing a hydrated environment that facilitates drug release and absorption. Hydrogels can be formulated as solutions, gels, or films, offering versatility in drug delivery applications.
Liposomes and nanoparticles are utilized as carriers for drug delivery to mucosal surfaces. These materials can encapsulate drugs, protecting them from degradation and facilitating their transport across mucosal barriers. Liposomes are composed of lipid bilayers, while nanoparticles can be made of various materials such as polymers, lipids, or metals, offering tailored drug release profiles and enhanced drug stability.
Mucoadhesive polymers are designed to adhere to mucosal surfaces, prolonging drug residence time and improving drug absorption. These materials can interact with mucin glycoproteins present on the mucosal epithelium, enhancing drug penetration and reducing drug loss. Examples of mucoadhesive polymers include chitosan, alginate, and carbopol.
Microneedles are tiny, minimally invasive structures that can penetrate the mucosal epithelium, allowing for precise drug delivery. These materials can be fabricated from dissolvable polymers or metals and can be coated with drug formulations. Microneedles offer the advantage of targeted drug delivery to specific mucosal sites, minimizing systemic exposure and improving therapeutic outcomes.
Mucosal drug delivery systems for the nasal route are utilized for local and systemic drug administration. They offer advantages such as rapid drug absorption, avoidance of first-pass metabolism, and direct access to the central nervous system. Nasal drug delivery is commonly employed for the treatment of allergies, nasal congestion, and systemic drug delivery, including vaccines and peptides.
Mucosal drug delivery systems for the oral cavity provide an alternative to traditional oral dosage forms. They can enhance drug absorption through the buccal or sublingual mucosa, bypassing the gastrointestinal tract and hepatic metabolism. Oral mucosal drug delivery is utilized for drugs with poor oral bioavailability, rapid drug onset, and localized oral conditions.
Mucosal drug delivery systems for the ocular route offer targeted drug delivery to the eye, improving drug bioavailability and reducing systemic side effects. These systems include ophthalmic gels, inserts, and nanoparticles that can provide sustained drug release and prolonged contact time with ocular tissues. Ocular drug delivery is employed for the treatment of various eye conditions, including glaucoma, dry eye, and ocular infections.
Mucosal drug delivery systems for the pulmonary route are used for the treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Inhalation devices, including metered-dose inhalers and dry powder inhalers, deliver drugs directly to the lungs, achieving rapid onset of action and minimizing systemic exposure.
Mucosal drug delivery systems for the vaginal and rectal routes provide localized drug delivery for gynecological and gastrointestinal conditions. Vaginal drug delivery systems include gels, inserts, and rings, while rectal drug delivery systems include suppositories and enemas. These systems offer targeted drug delivery to the respective mucosal sites, ensuring optimal drug efficacy and patient comfort.
Mucosal drug delivery system materials play a crucial role in enabling targeted and efficient drug administration through various mucosal routes. Partnering with Protheragen-ING, a reputable supplier, ensures the availability of high-quality excipients and supports the development of stable and efficacious pharmaceutical products. If you have any excipient requirements, please contact us by phone or email, and we will respond within 2-4 working days.
Cat | Product Name | Cas | Details | Chemical Structure |
---|---|---|---|---|
PIE-0151 | Disodium edetate (EDTA) | 6381-92-6 | View Details |
![]() |
PIE-0159 | carboxymethylcellulose sodium | 9085-26-1 | View Details |
![]() |
PIE-0160 | carbomer 934P | 9007-16-3 | View Details |
![]() |
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed